By Fineline Cube Leios Therapeutics, an innovative aesthetic therapies company, announced on August 31, 2026 that it has signed an exclusive licensing agreement with China Medical System Holdings Limited (CMS) (HKG: 0867) for 10XB‑101, a proprietary injectable therapy containing polidocanol, alongside a related strategic equity investment.
Deal Structure
| Item | Detail |
|---|---|
| Licensor | Leios Therapeutics (innovative aesthetic therapies company) |
| Licensee / Investor | China Medical System Holdings Limited (CMS), HKG: 0867 |
| Product | 10XB‑101 — proprietary injectable therapy containing polidocanol |
| Territory | Greater China: China including Hong Kong and Macau, excluding Taiwan |
| Rights Granted | Exclusive development, manufacturing, and commercialization |
| Licensor Economics | Upfront payment + regulatory & commercial milestone payments + royalties on future net sales |
| Parallel Transaction | CMS to make a strategic equity investment in Leios |
| Announcement Date | 31 Aug 2026 |
Under the agreement, Leios will also support the advancement of the 10XB‑101 clinical development program.
Product Profile & Mechanism of Action
- Positioning: Best‑in‑class minimally invasive injectable treatment designed to reduce focal fat deposits and enhance body contouring outcomes
- Active Ingredient: Polidocanol — a synthetic non‑ionic detergent that induces targeted adipolysis (localized fat‑cell destruction)
- Clinical Stage: Phase II clinical trials completed for the submental fat reduction indication (double‑chin fat)
Market Impact & Outlook
- China Aesthetics Boom: Injectable, minimally invasive fat‑reduction products address fast‑growing demand in China’s medical aesthetics market, where surgical liposuction alternatives remain limited.
- Best‑in‑Class Ambition: With Phase II trials already completed in submental fat reduction, 10XB‑101 enters the licensing stage with de‑risked clinical proof points ahead of pivotal China development.
- Aligned Interests: The combination of milestone‑based economics, royalties, and an equity stake gives CMS upside in both the product and the company, while funding Leios’ continued clinical program.
- Portfolio Fit for CMS: The deal extends China Medical System’s footprint in aesthetic and consumer healthcare products beyond its established pharmaceutical base.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory approvals, milestone payments, and commercialization of 10XB‑101. Actual results may differ due to risks including trial outcomes, regulatory timelines, market adoption, and competitive dynamics.-Fineline Info & Tech